Importance of a Previous Allergy to an Iodinated Contrast Agent in the Administration of Gadopentetate Dimeglumine

Abstract

Get full access to this article

View all access options for this article.

References

Runge

V.M.

, Bradley

W.G.

, Brant-Zawadzki

M.N.

, Cravling

M.J.

, De Simone

D.N.

, Dean

B.L.

. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 1991; 181: 701–9.

Goldstein

H.A.

, Kashanian

F.K.

, Blumeti

R.F.

, Holyoak

W.L.

, Hugo

F.P.

, Blumenfield

D.M.

. Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology 1990; 174: 17–23.

Nelson

K.L.

, Gifford

L.N.

, Laubert-Huber

, Gross

C.A.

, Lasser

T.A.

. Clinical safety of gadopentetate dimeglumine. Radiology 1995; 196: 439–43.

Tardy

, Guy

, Barrai

, Page

, Ollagnier

, Bertrand

J.C.

. Anaphylactic shock induced by intravenous gadopentetate dimeglumine (letter). Lancet 1992; 339: 494.

Russell

E.J.

, Schaible

T.F.

, Dillon

, Drayer

, Lipuma

, Mancuso

. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. Am J Neuroradiol 1989; 10: 53–63.